Cargando…

Repurposing of approved drugs with potential to interact with SARS-CoV-2 receptor

Respiratory transmission is the primary route of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection. Angiotensin I converting enzyme 2 (ACE2) is the known receptor of SARS-CoV-2 surface spike glycoprotein for entry into human cells. A recent study reported absent to low expressio...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahsan, Tamim, Sajib, Abu Ashfaqur
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8006196/
https://www.ncbi.nlm.nih.gov/pubmed/33817352
http://dx.doi.org/10.1016/j.bbrep.2021.100982
_version_ 1783672265378889728
author Ahsan, Tamim
Sajib, Abu Ashfaqur
author_facet Ahsan, Tamim
Sajib, Abu Ashfaqur
author_sort Ahsan, Tamim
collection PubMed
description Respiratory transmission is the primary route of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection. Angiotensin I converting enzyme 2 (ACE2) is the known receptor of SARS-CoV-2 surface spike glycoprotein for entry into human cells. A recent study reported absent to low expression of ACE2 in a variety of human lung epithelial cell samples. Three bioprojects (PRJEB4337, PRJNA270632 and PRJNA280600) invariably found abundant expression of ACE1 (a homolog of ACE2 and also known as ACE) in human lungs compared to very low expression of ACE2. In fact, ACE1 has a wider and more abundant tissue distribution compared to ACE2. Although it is not obvious from the primary sequence alignment of ACE1 and ACE2, comparison of X-ray crystallographic structures show striking similarities in the regions of the peptidase domains (PD) of these proteins, which is known (for ACE2) to interact with the receptor binding domain (RBD) of the SARS-CoV-2 spike protein. Critical amino acids in ACE2 that mediate interaction with the viral spike protein are present and organized in the same order in the PD of ACE1. In silico analysis predicts comparable interaction of SARS-CoV-2 spike protein with ACE1 and ACE2. In addition, this study predicts from a list of 1263 already approved drugs that may interact with ACE2 and/or ACE1 and potentially interfere with the entry of SARS-CoV-2 inside the host cells.
format Online
Article
Text
id pubmed-8006196
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-80061962021-03-29 Repurposing of approved drugs with potential to interact with SARS-CoV-2 receptor Ahsan, Tamim Sajib, Abu Ashfaqur Biochem Biophys Rep Research Article Respiratory transmission is the primary route of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection. Angiotensin I converting enzyme 2 (ACE2) is the known receptor of SARS-CoV-2 surface spike glycoprotein for entry into human cells. A recent study reported absent to low expression of ACE2 in a variety of human lung epithelial cell samples. Three bioprojects (PRJEB4337, PRJNA270632 and PRJNA280600) invariably found abundant expression of ACE1 (a homolog of ACE2 and also known as ACE) in human lungs compared to very low expression of ACE2. In fact, ACE1 has a wider and more abundant tissue distribution compared to ACE2. Although it is not obvious from the primary sequence alignment of ACE1 and ACE2, comparison of X-ray crystallographic structures show striking similarities in the regions of the peptidase domains (PD) of these proteins, which is known (for ACE2) to interact with the receptor binding domain (RBD) of the SARS-CoV-2 spike protein. Critical amino acids in ACE2 that mediate interaction with the viral spike protein are present and organized in the same order in the PD of ACE1. In silico analysis predicts comparable interaction of SARS-CoV-2 spike protein with ACE1 and ACE2. In addition, this study predicts from a list of 1263 already approved drugs that may interact with ACE2 and/or ACE1 and potentially interfere with the entry of SARS-CoV-2 inside the host cells. Elsevier 2021-03-29 /pmc/articles/PMC8006196/ /pubmed/33817352 http://dx.doi.org/10.1016/j.bbrep.2021.100982 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Research Article
Ahsan, Tamim
Sajib, Abu Ashfaqur
Repurposing of approved drugs with potential to interact with SARS-CoV-2 receptor
title Repurposing of approved drugs with potential to interact with SARS-CoV-2 receptor
title_full Repurposing of approved drugs with potential to interact with SARS-CoV-2 receptor
title_fullStr Repurposing of approved drugs with potential to interact with SARS-CoV-2 receptor
title_full_unstemmed Repurposing of approved drugs with potential to interact with SARS-CoV-2 receptor
title_short Repurposing of approved drugs with potential to interact with SARS-CoV-2 receptor
title_sort repurposing of approved drugs with potential to interact with sars-cov-2 receptor
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8006196/
https://www.ncbi.nlm.nih.gov/pubmed/33817352
http://dx.doi.org/10.1016/j.bbrep.2021.100982
work_keys_str_mv AT ahsantamim repurposingofapproveddrugswithpotentialtointeractwithsarscov2receptor
AT sajibabuashfaqur repurposingofapproveddrugswithpotentialtointeractwithsarscov2receptor